A
Annogen at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Annogen brings 3 presentations to ESGCT 2026 in Hamburg. Its work centres on the regulatory DNA that decides where and when a therapeutic gene switches on. One project found a promoter that responds to neuroinflammation for brain gene therapy, and another evolved an AAV8 capsid towards liver-specific delivery.
| Organization | ESGCT 2026 Attendance |
|---|---|
A Annogen Amsterdam, Netherlands | |
Designs and licenses synthetic promoters and enhancers, screened at scale in relevant cells and in vivo, for gene and cell therapies. | Poster Wed Oct 28 1:30pm–3:30pm Directed Evolution of AAV8 for Liver-Specific Transduction through VP1-restricted Mutagenesis and Barcode-Tracking Poster Wed Oct 28 1:30pm–3:30pm Identification and in vivo validation of a neuroinflammation-responsive promoter for CNS gene therapies Poster Wed Oct 28 1:30pm–3:30pm Tailored non-coding regulatory elements engineering for gene and cell therapy using massively parallel in vitro and vivo validation |
Instantly find 20 buyers from Annogen
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction